Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
- To demonstrate the superiority of CHF 5993 200/6/12.5 pMDI compared to CHF 1535 200/6 pMDI in terms of change from baseline in pre-dose FEV1 at Week 26. - To demonstrate the reduction of moderate and severe asthma exacerbations rate with CHF 5993 200/6/12.5 pMDI compared to CHF 1535 200/6 pMDI during the entire 52-week treatment period.
Inclusion criteria
- uncontrolled asthma